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S164 Oral Presentationsdiscovery approach identical to that we employed for elafin, we first
analyzed plasma pooled from ten patients with and ten without GI
GVHD. We identified 164 candidate proteins that were increased
at least 1.5 fold, and two lead candidates, REG3a and CEACAM1,
were preferentially expressed in the GI tract and measurable by
ELISA. We then validated these two candidates in plasma from 570
BMT patients: 113 GI GVHD; 223 no GVHD; 52 non-GVHD
(e.g. infectious) enteritis; and 182 skin onlyGVHD.Groups were bal-
anced for age, myeloablative conditioning and sample collection. Un-
related and HLA-mismatched donors were over-represented in the
GVHD patient groups. REG3a levels were two to four fold higher
in the GI GVHD group compared to all others (mean6SEM in ng/
ml: 245640, 6468, 74618, 112622, respectively, p\ 0.004). The
area under the curve (AUC) of the receiver operating characteristic
(ROC) curve of GI GVHD with respect to non-GVHD enteritis
was 0.75 (95%CI, 0.66-0.82). Similar differences between patient
groups were seen with CEACAM1, but including CEACAM1 in
a composite ROC curve of both markers performed no better than
REG3a alone (AUC 5 0.75). Thus, subsequent analyses were per-
formed on REG3a. We divided patients with GI symptoms (n 5
165) into two equal groups based on the median concentration of
REG3a: low (\ 65 ng/ml, n 5 83) and high ($ 65 ng/ml, n 5 82).
The REG3ahigh group developed more severe GVHD, had higher
1year non-relapse mortality (NRM), and lower 1 year overall survival
(OS), than the REG3alow group (Table 1). KRT18 has previously
been reported as a marker for liver/GI GVHD (Blood, 114:702-
708); we measured its levels on the same patient samples and found
that while levels were significantly different in GI GVHD than in
non-GVHD enteritis (p5 0.01), they were not significantly different
between GI and Skin GVHD (p 5 0.5), and they did not correlate
with GVHD severity, NRM or OS (Table 1). We have identified
and validatedREG3a, aC-type lectinwhoseGI expression is increased
in response to inflammatory stimuli such as bacteria, mucosal damage
or inflammatory bowel disease (Science, 313:1126-1130), as a diagnos-
tic biomarker of GI GVHD with significant prognostic value.34
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Introduction: Relapse is a major cause of hematopoietic cell trans-
plant (HCT) failure. Successful recovery of immunity against leuke-
mia treated with HCT (GVL immunity) is important in preventing
relapse. Thus, assays measuring GVL immunity could identify pa-
tients at risk of disease relapse. There is an association between re-
constitution of GVL immunity and herpesvirus specific immunity
(Parkman et al, BBMT 2006). Here we evaluated multiple assays
of anti-EBV/VZV/HHV6 immunity for their suitability to serve as
surrogates for GVL immunity and global antimicrobial immunity.
Patients &Methods:On day 56 post-transplant, we studied 46 allo-
HCT recipients for AML, who did not develop GVHD by day 56.
Blood mononuclear cells were stimulated with viral lysate from
EBV,HHV6 orVZV, or overlappingEBNA3, LMP112 orU54 pep-
tides, incubated overnight, stained for CD3, CD4, CD8, IFNg,
TNFa and IL2 and analyzed by flow cytometry. Patients were
followed for relapse and definite (microbiologically documented)Table 1. REG3a at onset of GI symptoms correlates with maximum
Maximum GVHD Grade
0 II-IV p-val
Low REG3a (%,95%CI) 45% (35%,55%) 55% (45%,65%) <0.0
High REG3a (%,95%CI) 17% (11%,27%) 83% (73%,89%)
Low KRT18 (%,95%CI) 34% (24%,45%) 66% (55%,76%) 0.5
High KRT18 (%,95%CI) 29% (20%,40%) 71% (60%,80%)infections. Absolute counts of each specific T cell subset were com-
pared between patients who did vs. did not relapse (or did vs. did
not develop at least one infection between day 56 and 180) using
Mann-Whitney test. Subsets with lowest p values were combined
into a scoring system, where for each subset, a score of 1 was assigned
to patients that had absolute counts above a cutoff, determined as the
mean between the highest value in patients who relapsed or developed
at least one infection and the nearest highest value.
Results:The following subset counts showed the highest association
with relapse: VZV specific CD4T cells producing IFNg, EBV lysate
specific CD8T cells producing IFNg and IL2, BZLF1 specific CD4
T cells producing IL2 with IFNg or TNFa, and BZLF1 specific T
cells producing TNFa and IL2. When the scores of these 5 subsets
were combined, a score of\1 was 100% sensitive and 78% specific
for relapse. The following subsets showed the highest association
with infections: U54 specific CD8 T cells producing TNFa,
EBNA3 specific CD4 T cells producing TNFa and IL2, and EBV
lysate specific CD8 T cells producing IFNg, TNFa and IL2. The
score of\ 1 was 100% sensitive and 36% specific for developing
at least one infection between day 56 and 180.
Conclusion: Herpesvirus specific T cell counts can serve as surro-
gates of both GVL immunity and global antimicrobial immunity.
They are highly sensitive but only moderately specific for relapse
and infections.35
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Our immune system interacts dynamically with our microbial
flora. Perturbing this balance can lead to pathological inflammation.
Prior animal and clinical studies of allogeneic hematopoietic stem
cell transplantation (HSCT) suggest that variations in gut flora can
predispose or protect against graft-versus-host disease (GVHD).
Gut decontamination as GVHD prophylaxis, however, gave mixed
results, and our knowledge of the gut microbiota was limited to
the 20-30% of species that can be cultured. Novel methodology, in-
cluding 16s ribosomal DNA sequencing, allows more complete
characterization of the gut flora. We thus revisited whether manip-
ulation of gut flora can minimize GVHD.
We used a MHC-disparate B10BR/B6 mouse model for allo-
HSCT and found that GVHD leads to changes in gut flora, particu-
larly in the distal ileum. Shifts in representationbybacterial families re-
sult in a nearly complete takeover by Lactobacillaceae and loss of
several familiesofFirmicutes (Table).These changes are readily repro-
ducible, includingwith individually-housedmice. This pattern of flora
associated with GVHD was distinct from patterns found in control
groups: HSCT recipients without GVHD, mice with dextran sulfate
sodium-induced colitis, and mice treated with osmotic laxatives.
Potential mechanisms behind this characteristic GVHD-associ-
ated flora are continuing to be explored, but thus far do not appear
to be due to changes in numbers of Paneth cells, expression of
IL22 or the antimicrobial molecule Reg3g, or luminal levels of
IgA. Interestingly, the bacterial density in the ileum, quantified by
copies of 16s rDNA, is similar in mice with or without GVHD after
HSCT, and is twice that of untreated mice.
We then performed experiments evaluating flora manipulation
prior to HSCT. We found that ampicillin treatment followed by
a 2 week recovery results in complete loss of Lactobacillaceae andGVHD grade, 1 year NRM and 1 year OS
ue 1 year NRM p-value 1 year OS p-value
01 24% (15%,35%) <0.001 68% (58%,79%) 0.001
49% (38%,60%) 43% (33%,56%)
4 39% (29%,51%) 0.9 57% (47%,69%) 0.22
33% (23%,44%) 54% (44%,66%)
Oral Presentations S165expansion of remaining families of Firmicutes (Table). UponHSCT,
these mice developed fulminant GVHD compared to their counter-
parts who did not receive ampicillin (p\ .01). Interestingly, oral ga-
vage with Lactobacillaceae following ampicillin appears to prevent
exacerbation of GVHD.
Altogether, our results suggest that during GVHD, an increase of
Lactobacillaceae in the gut may be a compensatory mechanism to re-
duce GVHD severity. Moreover, antibiotics prior to HSCT could
predispose to GVHD, while the administration of Lactobacillaceae
can be explored as GVHD prophylaxis.
Table 1. Bacterial family representation in ileal contents
% other
% Lactobacillaceae FirmicutesNormal B6 mice 42±3 26±1
HSCT mice without GVHD 54±2 27±2
HSCT mice with GVHD 95±2 2±0.5
B6 mice after ampicillin and recovery 0±0.1 98±136
SINGLE NUCLEOTIDE POLYMORPHISM (SNP)-BASED PREDICTIVE
MODELS FOR GRAFT-VERSUS-HOST DISEASE (GVHD) IDENTIFY HIGH
RISK PATIENTS FOR OVERALL AND ORGAN SPECIFIC GVHD FOLLOWING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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Introduction: The present study attempted to identify potential
predictive SNP marker associating with the risk of acute (aGVHD)
or chronic GVHD (cGVHD) and organ specific GVHDs. In addi-
tion, SNP markers predicting transplant outcomes such as overall
survival (OS), relapse free survival (RFS) or non relapse mortality
(NRM) were also analyzed with 259 SNPs in 54 genes which are po-
tentially involved in the pathogenesis of GVHD.
Materials andMethods: 394 pairs of donors and recipients were in-
cluded and their germline DNA samples were genotype for 259
SNPs in 54 genes using MALDI-TOF based platform. The Risk
of aGVHD/cGVHD and organ specific GVHD were evaluated as
well as RFS, NRM and OS in patients receiving related donor trans-
plantation (n 5 303). After multivariate analyses, the predictive
model generated by combination of clinical and genetic SNP
markers were attmpted to stratify patients into low (\Q1), moderate
(Q2,3) and high risk groups (Q4), which were to be validated in 84
pairs receiving MUD transplantation. Finally, we performed C-sta-
tistic analysis for each transplant outcome in a pooled population (n
5 394).
Results: Several SNP markers in the cytokine, apoptosis, TGF-b or
PDGF mediated pathways were identified as potential predictive of
aGVHD/cGVHD. Of interest,NOS2 (nitric oxide 2) was associated
with the risk of cutaneous or aGVHD. PDGF-mediated pathway
was involved in the pathogenesis of cutaneous GVHD. These pre-
dictive models generated with both clinical and genetic factors
were statistically significant (P\ 0.001) except for overall cGVHD
(p 5 0.07). The genetic predictive models have been replicated in
validation cohort in terms of skin cGVHD (p \ 0.0001), skin
aGVHD (p 5 0.0219), aGVHD (p 5 0.0274), and RFS (p 5
0.0166). The C-statistics have been increased by median of 0.0745
(range 0.023-0.18, mean 0.0788) when adopted the predictive model
generated combined with clinical and genetic factors compared to
that generated only by clinical factors.
Conclusions: The present study suggested that 1) the predictive
models improved stratification of the patients according to their
transplant outcomes and the risk of GVHD (esp. organ specific
GVHD) using donor-/recipient-SNP markers, and 2) the predictive
models incorporating clinical and genetic factors were suggested to
enhance stratification power predicting the prognosis of transplant
patients and the risk of GVHD.37
UNIVERSAL ROLE FOR HLA-C AND KIR2DL LIGAND MISMATCH IN
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Donor HLA mismatching is a known risk factor for morbidity and
mortality after unrelated hematopoietic cell transplantation (HCT).
The frequency of donor and recipient HLA phenotypes differs be-
tween ethnically diverse populations, as does the incidence of acute
graft-versus-host disease (GVHD). Certain high-risk HLA mis-
matches are responsible for acute GVHD risk in the Japanese experi-
ence (Kawase et al Blood 2007). We tested the hypothesis that
clinical outcome after HLA-C mismatched unrelated HCT depends
on the specific mismatch combinations, and that risks are different de-
pending on theHLAphenotypes of the transplant population.The In-
ternational Histocompatibility Working Group dataset enables us to
compare clinical outcome between Caucasian and Japanese popula-
tions to test these hypotheses. High resolution HLA typing was avail-
able for the Japanese (n 5 5986) and Caucasian pairs (n 5 9379).
Multivariable Cox regression models adjusted for HLAmatching sta-
tus other than HLA-C and non-HLA factors known to influence
GVHD risk. In both Japanese and Caucasian recipients, the presence
of an HLA-C mismatch/KIR ligand match was associated with in-
creased risk of grades III-IV acute GVHD compared to an HLA-C
match (HR 1.69 [p \ 0.001] and 1.23 [p \ 0.001], respectively).
KIR2DL ligand mismatching had an even stronger effect among the
Japanese than the Caucasian recipients (HRs for HLA-C allele mis-
match and KIR mismatch in GVH direction were 2.51 (p\ 0.001)
and 1.21 (p5 0.017), respectively). Since it is known that certain mis-
matches that occur in the Japanese population occur very infrequently
(if at all) in theCaucasian population, and vice verse, we conducted the
sameanalysesbut limited to subjectswhohaveHLA-Cmismatchcom-
binations occurring in more than 10 subjects in both populations.
Compared to HLA-Cmatches, HLA-C mismatch/KIR ligand match
and HLA-C mismatch/KIR ligand mismatch were associated with
a statistically significantly increased risk of GVHD in Japanese (HR
1.39 [p5 0.003] andHR3.13 [p\0.001], respectively) but not inCau-
casian recipients (HR 1.18 [p 5 0.128] and HR 0.91 [p 5 0.588]).
These results suggest that the magnitude of risks associated with
HLA-C disparity after unrelated HCT may be different in recipients
of Japanese compared to Caucasian background, particularly in the
presence of a KIR ligandmismatch. Risks may also depend on the spe-
cific HLA-C allele mismatch combinations.
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A PROSPECTIVE PHASE I/II TRIAL OF BORTEZOMIB-BASED GRAFT-
VERSUS-HOST-DISEASE PROPHYLAXIS IN HLA-MISMATCHED UNRE-
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AND SURVIVAL
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Introduction: The challenge in RIC HSCT is to prevent GVHD
but maintain GVL and immunologic reconstitution. Bortezomib is
an excellent candidate immunomodulator. In addition to antitumor
activity via NF-kB and other pathways, it inhibits APC by attenuat-
ing TLR-4 mediated activation and cytokine production. In mouse
models, bortezomib preferentially and specifically depletes alloreac-
tive T cells, and prevents GVHD without impairing engraftment or
